
ELEV
Elevation Oncology Inc
- Overview
- Forecast
- Valuation
- Earnings
High
0.377
Open
0.377
VWAP
--
Vol
--
Mkt Cap
137.14M
Low
0.377
Amount
--
EV/EBITDA(TTM)
--
Total Shares
54.64M
EV
-27.78M
EV/OCF(TTM)
--
P/S(TTM)
--
Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021, is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors. EO-1022 is an ADC containing seribantumab.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
--
--
-0.275
+52.78%
--
--
-0.125
-43.18%
--
--
-0.133
-26.39%
Estimates Revision
The market is revising No Change the revenue expectations for Elevation Oncology, Inc. (ELEV) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -1.78%.
EPS Estimates for FY2025
Revise Upward

+30.47%
In Past 3 Month
Stock Price
Go Down

-1.78%
In Past 3 Month
5 Analyst Rating

-1.86% Downside
Wall Street analysts forecast ELEV stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELEV is 0.37 USD with a low forecast of 0.36 USD and a high forecast of 0.38 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
5 Hold
0 Sell
Hold

-1.86% Downside
Current: 0.377

Low
0.36
Averages
0.37
High
0.38

-1.86% Downside
Current: 0.377

Low
0.36
Averages
0.37
High
0.38
H.C. Wainwright
Swayampakula Ramakanth
Buy -> Neutral
downgrade
2025-06-10
Reason
H.C. Wainwright
Swayampakula Ramakanth
Price Target
2025-06-10
downgrade
Buy -> Neutral
Reason
H.C. Wainwright analyst Swayampakula Ramakanth downgraded Elevation Oncology to Neutral from Buy with a 36c price target, down from $1.0, after the company entered into a definitive merger agreement with Concentra Biosciences that includes a proposal to be acquired for a purchase price of 36c per share in cash.
William Blair
William Blair
Outperform -> Market Perform
downgrade
$NULL
2025-06-09
Reason
William Blair
William Blair
Price Target
$NULL
2025-06-09
downgrade
Outperform -> Market Perform
Reason
William Blair downgraded Elevation Oncology to Market Perform from Outperform after Concentra Biosciences agreed to acquire Elevation for 36c in cash per share plus one non-tradeable contingent value right.
TD Cowen
Marc Frahm
Buy
to
Hold
downgrade
$NULL
2025-06-09
Reason
TD Cowen
Marc Frahm
Price Target
$NULL
2025-06-09
downgrade
Buy
to
Hold
Reason
TD Cowen analyst Marc Frahm downgraded Elevation Oncology to Hold from Buy after Concentra Biosciences agreed to acquire Elevation for 36c in cash per share plus one non-tradeable contingent value right. The firm views Elevation's planned acquisition as "likely the best path forward" for shareholders given the limited ability of the company to establish a clearly differentiated ADC program with its existing cash runway, the analyst tells investors.
Stephens & Co.
Sudan Loganathan
Buy
to
Hold
Downgrades
$5
2025-03-24
Reason
Stephens & Co.
Sudan Loganathan
Price Target
$5
2025-03-24
Downgrades
Buy
to
Hold
Reason
Stephens downgraded Elevation Oncology to Equal Weight from Overweight with a price target of $1, down from $5, following recent news regarding the discontinuation of development for EO-3021. The firm has updated its FY25 and FY26 loss forecasts to (48c) and (23c) from (66c) and (73c), respectively, to reflect lower opex as a result of the workforce reduction and elimination of EO-3021 Phase 1 clinical development. The company has shifted focus to their in-house developed preclinical asset EO-1022, a HER3-targeting ADC, with preclinical data expected at the AACR Annual Meeting, the analyst noted.
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Maintains
$6 → $1
2025-03-21
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$6 → $1
2025-03-21
Maintains
Strong Buy
Reason
Elevation Oncology announced that it has elected to discontinue development of EO-3021. EO-3021 is a Claudin 18.2 antibody-drug conjugate, which Elevation Oncology was developing for the treatment of advanced, unresectable or metastatic gastric and gastroesophageal junction cancers. Elevation Oncology will continue to advance EO-1022, a HER3 ADC for the treatment of patients with HER3-expressing solid tumors, and, in parallel, is initiating a process to evaluate strategic options to maximize shareholder value. The decision to discontinue clinical development of EO-3021 was based on data from the dose escalation and expansion stages of Elevation Oncology's Phase 1 trial, in which treatment with EO-3021 as a monotherapy demonstrated an objective response rate of 22.2% and a disease control rate of 72.2% among 36 evaluable patients with gastric or GEJ cancer and Claudin 18.2 in greater than or equal to20% of tumor cells at IHC 2+/3+. In the safety analysis of all enrolled patients, treatment with EO-3021 was observed to be generally well-tolerated, with an adverse event profile consistent with previously reported data, including minimal hematological toxicity and hepatotoxicity, and no peripheral neuropathy/hypoesthesia. "We are deeply disappointed by these results from our Phase 1 trial. Despite continuing to demonstrate differentiated safety as a more combinable ADC, updated efficacy data suggest that treatment with EO-3021 does not meet our bar for success and is insufficient to provide patients a competitive benefit-risk profile compared to other Claudin 18.2 ADCs in development," said Joseph Ferra, President and CEO of Elevation Oncology. "Based on these data, we have decided to discontinue further development of EO-3021. I want to express my tremendous gratitude to the patients, physicians and site coordinators who participated in the EO-3021 clinical trial." Ferra continued, "We are turning our focus to our potentially differentiated HER3 ADC, EO-1022, which incorporates glycan site-specific conjugation and is designed to address significant and emerging unmet needs in many HER3-expressing cancers. We look forward to presenting preclinical data supporting its potential at the AACR Annual Meeting next month. In parallel, we are initiating efforts to evaluate strategic options for the company. With cash into the second half of 2026 and a disciplined operating strategy, we are well-positioned to advance EO-1022 while working to identify and capitalize on the best opportunities to maximize value for our stakeholders."
Leerink Partners
Andrew Berens
Buy
to
Hold
Downgrades
$9 → $1
2025-03-21
Reason
Leerink Partners
Andrew Berens
Price Target
$9 → $1
2025-03-21
Downgrades
Buy
to
Hold
Reason
Leerink downgraded Elevation Oncology to Market Perform from Outperform with a price target of $1, down from $9, after the company announced that they will discontinue clinical development of EO-3021 based on updated data from a Phase 1 trial. Given the discontinuation of the lead asset and the early stage of development for EO-1022, the firm is moving to the sidelines pending greater visibility into the profile and commercial potential of EO-1022, the analyst tells investors.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Elevation Oncology Inc (ELEV.O) is -0.61, compared to its 5-year average forward P/E of -1.69. For a more detailed relative valuation and DCF analysis to assess Elevation Oncology Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-1.69
Current PE
-0.61
Overvalued PE
-0.07
Undervalued PE
-3.31
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-0.02
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.05
Undervalued EV/EBITDA
-1.08
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q1
YoY :
+9.85%
-10.84M
Operating Profit
FY2025Q1
YoY :
+32.73%
-14.21M
Net Income after Tax
FY2025Q1
YoY :
+4.35%
-0.24
EPS - Diluted
FY2025Q1
YoY :
+32.75%
-12.71M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
1
3.0M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ELEV News & Events
Events Timeline
2025-06-09 (ET)
2025-06-09
08:12:57
Elevation enters into agreement to be acquired by Concentra for 36c per share

2025-05-15 (ET)
2025-05-15
07:32:12
Elevation Oncology reports Q1 EPS (24c), consensus (18c)

2025-03-20 (ET)
2025-03-20
08:04:32
Elevation Oncology to discontinue development of EO-3021; Advancing EO-1022

Sign Up For More Events
Sign Up For More Events
News
7.0
06-15GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FLS, ELEV, MTWO, CRKN on Behalf of Shareholders
8.5
06-15GlobenewswireHAPPY FATHER’S DAY! and $HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Elevation Oncology, Inc. (NASDAQ: ELEV)
7.0
06-13GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRKN, ELEV, STR, VIGL on Behalf of Shareholders
Sign Up For More News
People Also Watch

INTS
Intensity Therapeutics Inc
0.304
USD
-5.30%

PXS
Pyxis Tankers Inc
2.996
USD
0.00%

RAPT
RAPT Therapeutics Inc
11.530
USD
0.00%

BRNS
Barinthus Biotherapeutics PLC
1.530
USD
0.00%

ARBK
Argo Blockchain PLC
0.300
USD
-4.46%

OM
Outset Medical Inc
17.810
USD
+1.54%

MDAI
Spectral AI Inc
2.520
USD
0.00%

DMYY
DMY Squared Technology Group Inc
12.700
USD
0.00%

ESHA
ESH Acquisition Corp
11.110
USD
-0.99%

CALC
CalciMedica Inc
3.780
USD
0.00%
FAQ

What is Elevation Oncology Inc (ELEV) stock price today?
The current price of ELEV is 0.377 USD — it has decreased -2.19 % in the last trading day.

What is Elevation Oncology Inc (ELEV)'s business?

What is the price predicton of ELEV Stock?

What is Elevation Oncology Inc (ELEV)'s revenue for the last quarter?

What is Elevation Oncology Inc (ELEV)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Elevation Oncology Inc (ELEV)'s fundamentals?

How many employees does Elevation Oncology Inc (ELEV). have?
